These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32808294)

  • 1. Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer's disease: 30 years of clinical use.
    Gavrilova SI; Alvarez A
    Med Res Rev; 2021 Sep; 41(5):2775-2803. PubMed ID: 32808294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrolysin improves symptoms and delays progression in patients with Alzheimer's disease and vascular dementia.
    Allegri RF; Guekht A
    Drugs Today (Barc); 2012 Apr; 48 Suppl A():25-41. PubMed ID: 22514793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Delayed effects of cerebrolysin in the prevention of cognitive impairment progression in the first degree relatives of patients with Alzheimer's disease: the role of the ApoE genotype].
    Selezneva ND; Gavrilova SI; Kolykhalov IV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(10. Vyp. 2):31-38. PubMed ID: 33205928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials.
    Gauthier S; Proaño JV; Jia J; Froelich L; Vester JC; Doppler E
    Dement Geriatr Cogn Disord; 2015; 39(5-6):332-47. PubMed ID: 25832905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cognitive impairment and tactics of using the drug Cerebrolysin. Resolution of the International Council of Experts (May 12, 2023)].
    Levin OS; Voznyuk IA; Illarioshkin SN; Tkacheva ON; Bogolepova AN; Vasenina EE; Gavrilova SI; Dokukina TV; Emelin AY; Lobzin VY; Mkhitaryan EA; Khatkova SE; Yakushin MA; Yanishevskiy SN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(9):121-130. PubMed ID: 37796079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrolysin in Alzheimer's disease.
    Antón Álvarez X; Fuentes P
    Drugs Today (Barc); 2011 Jul; 47(7):487-513. PubMed ID: 22013558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cerebrolysin in the treatment of cognitive impairment].
    Bogolepova AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(3):20-25. PubMed ID: 36946392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin.
    Alvarez XA; Cacabelos R; Sampedro C; Aleixandre M; Linares C; Granizo E; Doppler E; Moessler H
    Eur J Neurol; 2011 Jan; 18(1):59-68. PubMed ID: 20500802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cerebrolysin Treatment Reduces the Risk of Mild Cognitive Decline to Dementia in 1st-Degree Relatives of Alzheimer's Patients: A Prospective Comparative Study].
    Selezneva ND; Gavrilova SI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(8):90-97. PubMed ID: 37655416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination treatment in Alzheimer's disease: results of a randomized, controlled trial with cerebrolysin and donepezil.
    Alvarez XA; Cacabelos R; Sampedro C; Couceiro V; Aleixandre M; Vargas M; Linares C; Granizo E; García-Fantini M; Baurecht W; Doppler E; Moessler H
    Curr Alzheimer Res; 2011 Aug; 8(5):583-91. PubMed ID: 21679156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer's disease.
    Bae CY; Cho CY; Cho K; Hoon Oh B; Choi KG; Lee HS; Jung SP; Kim DH; Lee S; Choi GD; Cho H; Lee H
    J Am Geriatr Soc; 2000 Dec; 48(12):1566-71. PubMed ID: 11129744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficial effects of a neurotrophic peptidergic mixture persist for a prolonged period following treatment interruption in a transgenic model of Alzheimer's disease.
    Rockenstein E; Ubhi K; Pham E; Michael S; Doppler E; Novak P; Inglis C; Mante M; Adame A; Alvarez XA; Moessler H; Masliah E
    J Neurosci Res; 2011 Nov; 89(11):1812-21. PubMed ID: 21793038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrolysin: a review of its use in dementia.
    Plosker GL; Gauthier S
    Drugs Aging; 2009; 26(11):893-915. PubMed ID: 19848437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapeutic monitoring and prediction of the efficacy of neurotrophic treatment in patients with amnestic type of mild cognitive impairment].
    Gavrilova SI; Volpina OM; Kolykhalov IV; Fedorova YB; Selezneva ND; Ponomareva EV; Koroev DO; Kamynina AV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(8):27-38. PubMed ID: 28884714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical experience with Cerebrolysin.
    Molloy DW; Standish TI
    J Neural Transm Suppl; 2000; 59():293-300. PubMed ID: 10961441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Features and outcomes of drugs for combination therapy as multi-targets strategy to combat Alzheimer's disease.
    Sahoo AK; Dandapat J; Dash UC; Kanhar S
    J Ethnopharmacol; 2018 Apr; 215():42-73. PubMed ID: 29248451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The therapeutic potential of cerebrolysin in the preventive therapy of Alzheimer's disease].
    Gavrilova SI; Fedorova IaB; Kolykhalov IV; Odinak MM; Emelin AIu; Kashin AV; Selezneva ND; Kalyn IaB; Roshchina IF
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(8):24-8. PubMed ID: 18833104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer's disease.
    Wei ZH; He QB; Wang H; Su BH; Chen HZ
    J Neural Transm (Vienna); 2007; 114(5):629-34. PubMed ID: 17318304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Brain AT2R-a Potential Target for Therapy in Alzheimer's Disease and Vascular Cognitive Impairment: a Comprehensive Review of Clinical and Experimental Therapeutics.
    Ahmed HA; Ishrat T
    Mol Neurobiol; 2020 Aug; 57(8):3458-3484. PubMed ID: 32533467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin E for Alzheimer's dementia and mild cognitive impairment.
    Farina N; Llewellyn D; Isaac MGEKN; Tabet N
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD002854. PubMed ID: 28418065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.